Patients with sickle cell disease may soon have two new treatments to try.
On Tuesday, a U.S. Food and Drug Administration advisory committee will weigh the merits of a new gene therapy for the painful, inherited condition, which typically strikes Black people.
The agency is expected to make a decision on that therapy in early December, and it also plans to decide on a second new treatment before year’s end, the Associated Press reported.
The treatment being reviewed Tuesday is based on CRISPR technology, a gene-editing tool. The inventors of that tool won the Nobel Prize in 2020 for their work, the AP reported.
